The California Pharmacy and Therapeutic (P&T) Committee will hold a hybrid meeting on April 15, 2026 from 12:30 PM to 2:30 PM PST to discuss updates to the MTUS drug list, an informational update on physician and pharmaceutical fee schedules, and other formulary issues, including ibuprofen price outliers.

Highlights from the proposed meeting agenda include:

• Updated MTUS drug list (effective April 30, 2026)
• Ibuprofen price outliers
• Pregabalin and gabapentin
• Cyclobenzaprine and tizanidine
• Duloxetine

The agenda also notes that additional topics are anticipated for discussion at the Committee’s July meeting, including biosimilar utilization trends, GLP-1 products, extended use of proton pump inhibitors, and a review of anticonvulsant and migraine therapies.

The DWC is accepting public comments on the formulary drug list which may be submitted to Formulary@dir.ca.gov.